Overview

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Status:
Active, not recruiting

Trial end date:
2022-07-15

Target enrollment:

Participant gender:

Summary

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Collaborator:

Genentech, Inc.

Treatments:

Azacitidine
Venetoclax